TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17400086
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (EPO) 600 IU/kg once weekly for 4 doses
Study: 15877947
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment based on traditional Chinese medical differentiation
Study: 16959151
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment
Study: 8633913
Drug: Protein-sparing therapy
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-sparing therapy group
Study: 1769603
Drug: Hydralazine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 40 mg per os every 6 hrs, plus sublingual nifedipine (used if diastolic pressure of 110 mmHg or more)
Study: 24661333
Drug: Degarelix 80
Normalized name: degarelix 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 80 mg
Study: 24661333
Drug: Degarelix 160
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 160 mg
Study: 24661333
Drug: Degarelix 240/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 240/80 mg (crossover from leuprolide)
Study: 24661333
Drug: Degarelix 240/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 240/160 mg (crossover from leuprolide)
Study: 22161728
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg annually for 6 years (Z6, n = 616)
Study: 22161728
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg annually for 6 years (Z6)
Study: 12198987
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide and 0.11% fluoride ion gel
Study: 9755033
Drug: 50 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Hz magnetic field exposure (20 microT, 200 mG)
Study: 350251
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate (800 mg)
Study: 350251
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium valproate (800 mg)
Study: 31619057
Drug: Intravenous busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous busulfan (BU) pre-transplant
Study: 26732142
Drug: Nebulized hypertonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline (3 mL, 4 times/day)
Study: 26732142
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline, 3 mL, 4 times/day)
Study: 12390102
Drug: R40C800 (Rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: R40C800 (Rabeprazole 20 mg + Amoxicillin 750 mg + Clarithromycin 400 mg, twice daily)
Study: 12390102
Drug: LAC (Lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (Lansoprazole + Amoxicillin + Clarithromycin)
Study: 1976543
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 tablets
Study: 31336497
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g soy nut diet for 8 weeks
Study: 28801554
Drug: Delayed fractional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed fractional dose regimen of the RTS,S malaria vaccine (0-1-7 month schedule, third dose at 20% of full dose)
Study: 15081178
Drug: Community consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community consultation (CC) and public disclosure (PD) activities conducted by investigators
Study: 11864862
Drug: Dietary magnesium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary magnesium intake less than 160 mg/d (less than half of the recommended dietary allowance)
Study: 10753423
Drug: Arlevert therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arlevert therapy
Study: 31588657
Drug: Rongliflozin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rongliflozin (20 mg with food in healthy participants)
Study: 31588657
Drug: Rongliflozin (10-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rongliflozin (10-50 mg once daily for 12 days in T2DM)
Study: 31588657
Drug: Rongliflozin (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rongliflozin (10-200 mg single ascending dose in healthy participants)
Study: 17906188
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of massage therapy
Study: 17906188
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days without massage therapy
Study: 16142136
Drug: Prépidil (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prépidil (prostaglandin gel)
Study: 28658164
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 0.06 mg/kg (group A)
Study: 28658164
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 0.08 mg/kg (group B)
Study: 19629461
Drug: Standard FK506-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FK506-based immunosuppressant regimen only (Control)
Study: 16958739
Drug: Natural mineral
Normalized name: ZINC OXIDE 8.25 g in 44 mL TOPICAL LOTION [Natural Mineral Formula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural mineral dietary supplement (NMDS), 1 l, swished twice a day
Study: 16958739
Drug: Placebo (de-ionized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (de-ionized water), 1 l, swished twice a day
Study: 16958739
Drug: Natural mineral
Normalized name: ZINC OXIDE 8.25 g in 44 mL TOPICAL LOTION [Natural Mineral Formula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural mineral dietary supplement (NMDS)
Study: 12864878
Drug: Perindopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment program
Study: 12864878
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls (no treatment or inconsistent treatment)
Study: 10695647
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) and pharmacotherapy initiated at the outset of treatment
Study: 10695647
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) alone first, then combination therapy for non-remitters
Study: 3215161
Drug: Relapse-prevention (RP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse-prevention (RP) treatment
Study: 29258724
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral radiocontrast (baseline)
Study: 22421690
Drug: Monthly antibiotic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly antibiotic treatment (ciprofloxacin or azithromycin) for 9 months
Study: 22421690
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 9 months
Study: 14519709
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg for weight <40 kg or 500 mg for weight ≥40 kg) administered orally 3 days a week for 168 days
Study: 14519709
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically packaged tablets)
Study: 1851785
Drug: Combined potassium‐losing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined potassium‐losing and ‐sparing diuretic (triamterene 50 mg plus hydrochlorothiazide 25 mg)
Study: 7226124
Drug: CDVFP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDVFP + MER (0.4 mg S.C. every four weeks)
Study: 7226124
Drug: CD/MF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD/MF + MER (0.4 mg S.C. every four weeks)
Study: 25758100
Drug: Type 1
Normalized name: Type 1 H substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 1 implant placement
Study: 19697206
Drug: Superficial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial injection of local anaesthetic prior to deep injection into the cervix
Study: 19697206
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection into the substance of the cervix (Control)
Study: 18389594
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (Ursosan), 3-month course of treatment
Study: 7994224
Drug: Treatment consisting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment consisting of cleaning, depuration and motivation
Study: 2455442
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 20 mg of PEP/20 ml of saline for 4 weeks
Study: 2455442
Drug: Weekly instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly instillation of 20 mg of PEP/20 ml of saline for 8 weeks after TUR
Study: 18289228
Drug: Balanced salt-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced salt-based high molecular weight HES solution (670/0.75)
Study: 18289228
Drug: Saline-based low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline-based low molecular weight HES solution (130/0.4)
Study: 1550052
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg manganese daily
Study: 22584544
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl wafer (100 μg)
Study: 22584544
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (100 μg)
Study: 20425759
Drug: FVB capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVB capsules
Study: 1952134
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (10 mg)
Study: 8951195
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (2 g)
Study: 7614898
Drug: Zidovudine syrup
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine syrup (2 mg/kg administered 6-hourly for 6 weeks)
Study: 1975321
Drug: Alteplase (tPA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (tPA, 100 mg infused intravenously over 3 h)
Study: 1975321
Drug: Heparin (12,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (12,500 U subcutaneously twice daily until discharge, starting 12 h after beginning the tPA or SK infusion)
Study: 1975321
Drug: SK and
Normalized name: Ispaghula husk and mebeverine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK and heparin
Study: 4913961
Drug: Oral ergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergotamine tartrate
Study: 28668386
Drug: No transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transplantation group (full course of rituximab-dose-dense chemotherapy)
Study: 21719078
Drug: Anti-IL-13 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-13 (6 mg/kg intravenously)
Study: 16352815
Drug: Deferoxamine (43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (43 mg/kg for 5.7 d/wk)
Study: 15285851
Drug: lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (30 mg per day for 4 days)
Study: 11919104
Drug: Nebulised levo-adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised levo-adrenaline (3 mg in 3 ml)
Study: 8864962
Drug: Sitostanol ester
Normalized name: disodium ascorbyl sitostanol phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitostanol ester margarine (3 g/day)
Study: 7053889
Drug: Sequential studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential studies
Study: 26582805
Drug: Continuous intraperitoneal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraperitoneal insulin infusion (CIPII)
Study: 794978
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 8 weeks
Study: 8398292
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (MMC, BCG-Tice, BCG-RIVM)
Study: 3297218
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisone (0.5 mg/kg body weight)
Study: 3297218
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisone (2.0 mg/kg body weight)
Study: 31327047
Drug: Low FODMAP
Normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low FODMAP diet plus Bacillus coagulans supplementation (109 B. coagulans spores and 400 mg inulin)
Study: 22843218
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (painful)
Study: 25879794
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (control)
Study: 15056094
Drug: Nurse-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered propofol sedation (NAPS)
Study: 16105183
Drug: Glycine (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (multiple intravenous doses)
Study: 6504708
Drug: Indacrinone enantiomer
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone enantiomer combinations (10 mg (−) enantiomer + 40, 90, and 140 mg (+) enantiomer)
Study: 730416
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg)
Study: 22331983
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamin B6 3 mg, vitamin B12 0.02 mg)
Study: 22331983
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acids (eicosapentaenoic and docosahexaenoic acid 600 mg)
Study: 12213517
Drug: D-amphetamine (AMPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (AMPH; 15 mg oral)
Study: 7745465
Drug: Heparin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (continuous intravenous infusion)
Study: 7745465
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of anticoagulants
Study: 28647169
Drug: Same-day preschool
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day preschool vaccinations (number of injections between ages four and six years)
Study: 28647169
Drug: Parent vaccine
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent vaccine anxiety (VAS>50)
Study: 25405571
Drug: Low-dose estradiol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estradiol (E2) 0.5 mg/day
Study: 15679621
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75 mg/day
Study: 23644225
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with UPPP
Study: 22013952
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 20% albumin
Study: 22013952
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of 4% gelatin
Study: 15228864
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.75 ml/kg along with 0.1% midazolam 50mg/kg (group B)
Study: 15228864
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.75 ml/kg (group A)
Study: 11953729
Drug: Indwelling catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling catheter injections
Study: 11953729
Drug: Insulin pens
Normalized name: insulin isophane Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pens with standard needles (Control)
Study: 9832299
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times a day for 4 days)
Study: 9832299
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg once a day for 4 days)
Study: 2553425
Drug: HPTH 1-38
Normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPTH 1-38 (all doses)
Study: 25877963
Drug: efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 400 mg
Study: 23131756
Drug: 400 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg/kg ivermectin
Study: 31982355
Drug: Follitropin epsilon
Normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin epsilon 75 IU daily
Study: 31982355
Drug: Follitropin alfa
Normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin alfa 150 IU daily
Study: 31493887
Drug: Peanut sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut sublingual immunotherapy (SLIT) with 2 mg/d peanut protein for up to 5 years
Study: 26788484
Drug: BTX-A injection
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BTX-A injection + EMG biofeedback
Study: 23338814
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate, 5 mg (N‐EST)
Study: 21146572
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g scFOS (control)
Study: 18271887
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (misoprostol vaginally)
Study: 18271887
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (vacuum aspiration)
Study: 12764372
Drug: AIDA protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDA protocol (consolidation therapy)
Study: 23469596
Drug: Electro-acupuncture combined
Normalized name: combinations of electrolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture combined with general intravenous anesthesia (Group D)
Study: 23469596
Drug: General intravenous
Normalized name: General intravenous anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General intravenous anesthesia (Group N)
Study: 20406937
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) treatment after induction
Study: 20406937
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF treatment
Study: 10215749
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine (30 g over 30 min)
Study: 10215749
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (10 g)
Study: 328526
Drug: R-75 strain
Normalized name: Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension [Biothrax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-75 strain live, attenuated, serum inhibitor-resistant influenza B vaccine
Study: 31483963
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human GM-CSF (sargramostim), 125 μg twice daily for 7 days, every other week for 24 weeks
Study: 31483963
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human GM-CSF (sargramostim)
Study: 25952547
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga intervention (8-week, twice-weekly)
Study: 19326174
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam, given orally 1 hour before 18F-FDG injection
Study: 17595888
Drug: R (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (current formulation)
Study: 8455331
Drug: Cefpodoxime (CPDX-PR)
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime (CPDX-PR) given orally twice a day at 100-200 mg for 5-21 days
Study: 19885413
Drug: Control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implants
Study: 17320023
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone
Study: 10567777
Drug: Ceftriaxone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone plus aminoglycoside with filgrastim (once daily for > or =5 days, > or =2 days, and until ANC > or =1.0x10(9)/l for 2 days)
Study: 10567777
Drug: Out-patient treatment
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient treatment (early discharge)
Study: 7600120
Drug: recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant hirudin (HBW 023, 0.35 mg/kg body wt SC)
Study: 678831
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg oxamniquine
Study: 678831
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg oxamniquine
Study: 30649485
Drug: Computed tomography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed tomography (CT)‐based image‐guided brachytherapy (IGBT) with whole‐pelvic radiotherapy and concurrent chemotherapy (76% of patients)
Study: 19801228
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine (CHX) gel
Study: 23172172
Drug: PRT-201 (0.0033
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 (0.0033 to 9 mg)
Study: 23172172
Drug: PRT-201 (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 (Low Dose)